Home » Archive

testnews

Syndication, testnews »

Rewarding High-Risk Innovation: The Case for Carried Interest

Posted by sandiegobiotech April 15th, 2013 .
No Comments

As Washington grapples with the deficit, nothing generates more emotion than tax “loopholes.” A priority “loophole” target in the budget that President Obama sent to Congress last week is the…

[[Click headline to continue reading.]]

More...

Syndication, testnews »

Strategies for Navigating the Life Sciences Capital Crunch

Posted by sandiegobiotech April 15th, 2013 .
No Comments

The need for innovation in healthcare has arguably never been greater.  A range of factors, from aging world populations to rising standards of living in developing countries, are poised to drive…

[[Click headline to continue reading.]]

More...

Syndication, testnews »

Ambit Biosciences Appoints to Board of Directors

Posted by sandiegobiotech April 15th, 2013 .
No Comments

SAN DIEGO, April 15, 2013 /PRNewswire/ — Ambit Biosciences Corporation today announced that David R. Parkinson, M.D., has been appointed to the company’s board of directors. Dr. Parkinson is a venture partner at New Enterprise Associates, a position h…

More...

Syndication, testnews »

FDA Asks ACADIA Pharmaceuticals, Inc. to Skip Late Stage Study and File NDA After Successful Results, Stock Up +5.65 (70.89%) @ 2:43 PM ET

Posted by sandiegobiotech April 15th, 2013 .
No Comments

Acadia Pharmaceuticals Inc. (ACAD), a biotechnology company with $5 million in annual sales, rose 43 percent in early trading after saying it will gain a U.S. regulatory review of its lead drug sooner than anticipated. Acadia increased to $11.37 at 9 a…

More...

Syndication, testnews »

Celgene Corporation’s Becomes PhRMA Board Chairman; Assume New Posts

Posted by sandiegobiotech April 12th, 2013 .
No Comments

SAN DIEGO, April 12, 2013 /PRNewswire-USNewswire/ — Robert J. Hugin, chairman and CEO of Celgene Corporation, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association’s annual meeting. Als…

More...

Syndication, testnews »

San Diego Life Sciences Roundup: Receptos IPO, Isis, Versant, & More

Posted by sandiegobiotech April 12th, 2013 .
No Comments

Some of San Diego’s public life sciences companies have been buoyed as the stock market has soared to new heights in recent weeks (for the year, the Dow is up 13 percent and the S&P 500 index 12…

[[Click headline to continue reading.]]

More...

Syndication, testnews »

Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals

Posted by sandiegobiotech April 11th, 2013 .
No Comments

How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…

[[Click headline to continue reading.]]

More...

Syndication, testnews »

FDA Asks ACADIA Pharmaceuticals, Inc. to Skip Late Stage Study and File NDA After Successful Results, Stock Up +3.20 (40.15%) @ 9:30 AM ET

Posted by sandiegobiotech April 11th, 2013 .
No Comments

Acadia Pharmaceuticals Inc. (ACAD), a biotechnology company with $5 million in annual sales, rose 43 percent in early trading after saying it will gain a U.S. regulatory review of its lead drug sooner than anticipated. Acadia increased to $11.37 at 9 a…

More...

Syndication, testnews »

Medical Marijuana, Inc. Reports Record First Quarter 2013 Revenue and Income

Posted by sandiegobiotech April 11th, 2013 .
No Comments

SAN DIEGO, April 11, 2013 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), a leading cannabis and hemp industry innovator, today is pleased to pre-announce its fourth quarter earnings. The company earned net income of approximately $5.52 million o…

More...

Syndication, testnews »

MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.)’s Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth in Recurrent Ovarian Cancer Model

Posted by sandiegobiotech April 11th, 2013 .
No Comments

SAN DIEGO, April 10, 2013 /PRNewswire/ — MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced the presentation of new data showing the ability of its mitochondrial inhibitor…

More...